EirGenix

EirGenix ROE

The Return on Equity (ROE) of EirGenix (6589.TWO) as of Oct 16, 2026 is -9.12 %. In the previous year, Return on Equity (ROE) was -7.54 % — a change of 20.87% (lower).

ROE

-9.12 %

YoY

20.87%

Last updated:

In 2025, EirGenix's return on equity (ROE) was -9.12 %, a 20.87% increase from the -7.54 % ROE in the previous year.

The EirGenix ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-17.62 TWD
Jan 1, 2019
-46.41 TWD
Jan 1, 2020
-54.66 TWD
Jan 1, 2021
-0.41 TWD
Jan 1, 2022
-1.08 TWD
Jan 1, 2023
-9.14 TWD
Jan 1, 2024
-7.54 TWD
Jan 1, 2025
-9.12 TWD
The EirGenix ROE history
YEARROEYoY
-9.12 %+20.87%
-7.54 %-17.44%
-9.14 %+744.73%
-1.08 %+164.89%
-0.41 %-99.25%
-54.66 %+17.77%
-46.41 %+163.47%
-17.62 %+15.34%
-15.27 %+77.41%
-8.61 %-54.86%
-19.07 %+16.07%
-16.43 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

EirGenix Stock analysis

What does EirGenix do? EirGenix Inc., headquartered in Taipei, Taiwan, operates in the Health Care sector within the Life Sciences Tools & Services industry. The company provides Contract Development & Manufacturing Organization (CDMO) services, including cell strain construction, clinical trial medicine manufacturing, analytical science, protein identification, and PIC/S-compliant manufacturing facilities for clinical trial drug production. Listed on 23 November 2016, EirGenix employs 170 people and focuses on biotechnology drug research and development. EirGenix is one of the most popular companies on Eulerpool.

ROE Details

Decoding EirGenix's Return on Equity (ROE)

EirGenix's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing EirGenix's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

EirGenix's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in EirGenix’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about EirGenix stock

Return on Equity (ROE) of EirGenix is -9.12 % in 2025.

Return on Equity (ROE) of EirGenix changed from -7.54 % to -9.12 %, representing a 20.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) EirGenix since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s EirGenix with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — EirGenix

All Key Metrics — EirGenix